Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors.

iScience · 2023 · PMC10405066 · PMID 37554452

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

PartB-Direct_ActD_vs_CFZ_Comparison – In part to avoid complications with marginally significant or non-significant genes, Carfilzomib (CFZ) and Actinomycin D were directly compared with DESeq2 (in a multivariate model that adjusts for cell line differences).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.